Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Troponin I-FS CRISPR/Cas9 KO Plasmid (h): sc-401530
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Troponin I-FS CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Troponin I-FS genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Troponin I-FS Antibody (C-11): sc-377451
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Troponin I-FS CRISPR/Cas9 KO Plasmid (h) | sc-401530 | 20 µg | $397.00 |
Overview
TNNI2 encodes fast skeletal muscle troponin I (Troponin I-FS), the inhibitory subunit of the troponin complex that regulates actin–myosin interactions in a Ca²⁺-dependent manner. By binding to tropomyosin and actin, Troponin I-FS helps switch the thin filament between relaxed and contractile states downstream of sarcomeric excitation–contraction coupling. TNNI2 activity integrates with calcium signaling, myofibrillogenesis, and muscle fiber-type–specific contractile programs that shape force production and fatigue resistance. Genetic perturbations affecting troponin regulation and sarcomere function are linked to inherited skeletal muscle contracture and myopathy phenotypes, making TNNI2 a relevant target for mechanistic studies of muscle physiology and disease-associated contractile defects.
Troponin I-FS CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TNNI2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TNNI2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TNNI2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Troponin I-FS protein expression.
This CRISPR knockout system enables efficient generation of TNNI2-deficient cell models for investigation of Troponin I-FS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TNNI2 exon(s) critical for Troponin I-FS function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TNNI2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Troponin I-FS CRISPR/Cas9 KO Plasmid (h) and Troponin I-FS CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TNNI2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Troponin I-FS HDR Plasmid (h) and Troponin I-FS HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TNNI2 homology arms to support homology-directed repair at defined TNNI2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.